Access

Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Content from this campaign

AI Drives Data Insights for Doctors and Their Patients
Dr. Lina Basel-Salmon has been treating rare disease patients at Schneider Children’s Medical Center of Israel and Beilinson Hospital at the Rabin Medical Center for 22 years. In the city of Petah Tikva where she practices, Dr. Basel-Salmon was...
Jun 14, 2022 10:30 AM ET
“All Patients Should Have Their Tumor Sequenced At Least Once”
This year’s American Society of Clinical Oncology (ASCO) 2022 Annual Meeting took place in person at the Hyatt Regency in Chicago and online, June 3-7. Thousands of oncology professionals, patient advocates, and industry representatives convened for the world’s largest clinical oncology meeting to discuss the latest scientific and...
Jun 13, 2022 1:10 PM ET
Exome Sequencing Reveals Misdiagnoses in Epidermolysis Bullosa Patients
DEBRA International has a simple mission: help patients and families dealing with epidermolysis bullosa (EB), a rare genetic condition that affects collagen production, making skin and other membranes quite fragile. In EB cases, the slightest pressure can cause skin damage, but it’s also a systemic disease, since the collagen protein...
Jun 1, 2022 10:00 AM ET
PRECISE-ILLUMINA Partnership Agreement
Unique large-scale population study will yield insights into Asian-specific diseases, improving population health, patient outcomes, and innovations in the local biomedical technology industry.
May 27, 2022 10:00 AM ET
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients With Rare Genetic Mutations to Targeted Therapy
SAN DIEGO, May 24, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and...
May 24, 2022 12:45 PM ET

Pages